Article Text

Download PDFPDF

Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection
Free
  1. Carlo Civardi,
  2. Alessandra Collini,
  3. Dinha Joan Geda,
  4. Claudio Geda
  1. Department of Neurology, ASL TO4, Ivrea, Piedmont, Italy
  1. Correspondence to Dr Carlo Civardi, Department of Neurology, ASL To4, Ivrea, Piedmont, Italy; c_civardi{at}yahoo.com

Statistics from Altmetric.com

The pandemic SARS-CoV-2 is dramatically spreading around the world. Patients with COVID-19 typically present with viral pneumonia and resultant life-threatening respiratory complications. Although little information is available regarding the neurological manifestations of COVID-19, there are a few reports that describe Guillain-Barré syndrome (GBS) as an acute presentation of SARS-CoV-2.1 2 Here, we report a new case of COVID-19 initially presenting with acute GBS. On 24 March 2020, a 72-year-old woman arrived at the emergency department of our hospital presenting with lumbar pain, lower limb weakness and paresthesia, which started abruptly and progressed within 2 days (table 1). In the previous 10 days she had fever (Tmax 38.5°C, 101.3°F), anosmia, hypogeusia, dry cough and sore throat lasting for 3 days. Neurological examination disclosed symmetric weakness Medical Research Council (MRC) grade 3/5 in both legs and feet and MRC grade 4/5 in both arms and hands, …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.